AVN 64.80 Increased By ▲ 0.63 (0.98%)
BAFL 30.90 Increased By ▲ 1.00 (3.34%)
BOP 4.73 Increased By ▲ 0.10 (2.16%)
CNERGY 3.87 Decreased By ▼ -0.02 (-0.51%)
DFML 13.44 Increased By ▲ 0.09 (0.67%)
DGKC 41.34 Increased By ▲ 0.49 (1.2%)
EPCL 46.23 Decreased By ▼ -0.77 (-1.64%)
FCCL 11.39 Increased By ▲ 0.39 (3.55%)
FFL 5.05 Decreased By ▼ -0.03 (-0.59%)
FLYNG 5.81 Increased By ▲ 0.04 (0.69%)
GGL 9.90 Increased By ▲ 0.15 (1.54%)
HUBC 64.06 Increased By ▲ 2.11 (3.41%)
HUMNL 5.67 Increased By ▲ 0.02 (0.35%)
KAPCO 27.83 Increased By ▲ 0.25 (0.91%)
KEL 2.13 Decreased By ▼ -0.02 (-0.93%)
LOTCHEM 24.35 Increased By ▲ 0.05 (0.21%)
MLCF 21.36 Increased By ▲ 0.64 (3.09%)
NETSOL 84.43 Increased By ▲ 1.33 (1.6%)
OGDC 87.80 Increased By ▲ 1.75 (2.03%)
PAEL 10.92 Increased By ▲ 0.12 (1.11%)
PIBTL 4.17 Increased By ▲ 0.03 (0.72%)
PPL 77.53 Increased By ▲ 1.34 (1.76%)
PRL 13.65 Decreased By ▼ -0.01 (-0.07%)
SILK 0.88 Decreased By ▼ -0.01 (-1.12%)
SNGP 41.75 Increased By ▲ 1.00 (2.45%)
TELE 5.89 Increased By ▲ 0.01 (0.17%)
TPLP 15.81 Increased By ▲ 0.16 (1.02%)
TRG 112.65 Increased By ▲ 2.55 (2.32%)
UNITY 13.97 Increased By ▲ 0.22 (1.6%)
WTL 1.14 Decreased By ▼ -0.01 (-0.87%)
BR100 4,048 Increased By 80.6 (2.03%)
BR30 14,467 Increased By 282.1 (1.99%)
KSE100 40,673 Increased By 801.8 (2.01%)
KSE30 15,190 Increased By 292.7 (1.96%)
Pakistan

Russia’s Sputnik-V maker contacts DRAP to seek permission for emergency use of its vaccine in Pakistan

  • The vaccine’s developers have said the shot has been found to be 91.4% effective in providing protection.
  • Chinese firm Anhui Zheifi Longcom Biopharmaceuticals Company Limited has also applied for phase-III clinical trial of its vaccine in Pakistan.
Published January 22, 2021
Follow us

Russia’s state-owned Sputnik-V company has filed an application seeking permission for the emergency use of its vaccine in Pakistan.

Russia has approached the Drug Regulatory Authority of Pakistan (Drap) for registration, an official of the Ministry of National Health Services (NHS) told DAWN. The Sputnik-V is a double-dose vaccine and will be administered by syringes. The vaccine’s developers have said the shot has been found to be 91.4% effective in providing protection.

Meanwhile, Chinese firm Anhui Zheifi Longcom Biopharmaceuticals Company Limited has also applied for phase-III clinical trial of its vaccine in Pakistan. The vaccine has been jointly developed by the Anhui Zheifi Longcom Biopharmaceuticals Company Limited and the Institute of Microbiology under the Chinese Academy of Sciences.

DRAP has already authorized the British firm Oxford-AstraZeneca and Chinese firm Sinopharm’s vaccines for use in the country. On Thursday, Shah Mahmood Qureshi announced that China has promised to provide 500,000 doses of the coronavirus vaccine to Pakistan by January 31.

According to data of the National Command and Operation Centre, 1,745 coronavirus cases were reported during the past 24 hours, with the virus claiming 47 more lives. 2,075 people have also recovered from COVID-19, taking the tally to 482,771.

Comments

Comments are closed.

Russia’s Sputnik-V maker contacts DRAP to seek permission for emergency use of its vaccine in Pakistan

Dar meets IMF review mission, apprises it of planned power sector reforms

After 29 successive losses, rupee sees some gain, settles at 267.89 against US dollar

We must put our house in order, says Asif after Peshawar mosque bombing

Corps commanders resolve to bring perpetrators of Peshawar attack to ‘exemplary justice’

Inflationary pressure expected to calm down gradually: Finance Division

KSE-100 jumps 800 points owing to optimism over IMF talks

Pakistan’s performance worsens, rank remains same in corruption perception index

Barrick Gold makes first payment of $3mn to Balochistan govt

India’s Adani says to keep investing in Israel after Haifa port takeover

Indus Motor to shut down plant for two weeks